ITI Pharma and Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV: ₹ 14.13 as on 18-04-2024
Fund Performance
77 people have invested ₹ 1L in ITI Pharma and Healthcare Fund Direct Growth in the last three months
About the ITI Pharma and Healthcare Fund Direct Growth
ITI Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 11 November, 2021. The fund is managed by . The fund could potentially beat inflation in the long-run.
Key Parameters
- ITI Pharma and Healthcare Fund Direct Growth has ₹160 Cr worth of assets under management (AUM) as on Mar 2024 and is less than category average.
- The fund has an expense ratio 0.4.
ITI Pharma and Healthcare Fund Direct Growth Overview
 | 0.43% |
 Benchmark | S&P BSE Healthcare PR |
 | ₹160 Cr |
 | 11 November, 2021 |
 | ₹5000/₹500 |
 Exit Load | 1% |
 | No Lock-in |
 TurnOver | 22.62% |
ITI Pharma and Healthcare Fund Direct Growth Distribution as on (31-Mar-24)
Size breakup
Large cap
40.8%
Mid cap
28.3%
Small cap
28.2%
Sector Allocation
Health
97.1%
Basic Materials
2.9%
Top Holdings of ITI Pharma and Healthcare Fund Direct Growth as on (31-Mar-24)
Equity Holdings37
ITI Pharma and Healthcare Fund Direct Growth: Monthly Changes Updates
All changes are between Jan'24 and Mar'24
Fund Performance
- This fund’s returns stands at 0.62% whereas the fund’s underlying benchmark Nifty 500 returns stands at -0.47% as on Mar'24
- This fund outperformed Nifty 500 by 1.09% in Mar'24
AUM Change
- AUM of the fund stands at 160.4 Cr as of Mar'24
- AUM increased by 3.5 Cr between Mar'24 and Feb'24
Fund Portfolio Changes
Gainers & Losers in ITI Pharma and Healthcare Fund Direct Growth portfolio Returns for the month of Mar
Top Growth Drivers | 1M Return |
|---|---|
 Max Healthcare Institute Ltd | 16.9% |
Mankind Pharma Ltd | 12.3% |
Peer Analysis
ITI Pharma and Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 15.74% since inception which is less than its category average return of 20.36%
Fund Allocations
This fund has an allocation of 98.12% in Equity, 0% in Debt and 1.88% in Cash related instruments
AUM size ₹160 Cr
This fund has AUM of ₹160 Cr which is less than its category average of ₹ 1652 Cr
Expense Ratio 0.43%
This fund has an expense ratio of 0.43% which is less than its category average expense ratio of 1.45%
Frequently Asked Questions
The current NAV of ITI Pharma and Healthcare Fund Direct Growth is ₹14.13 as on 18-Apr-2024.
Existing (Absolute + CAGR) as on 18-Apr-2024.
ITI Pharma and Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 4.25% | 4.25% |
6 Month Returns | 24.02% | 24.02% |
1 Year Returns | 49.78% | 49.78% |
3 Years Returns | 0% | 0% |
5 Years Returns | 0% | 0% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.43% as on March 2024
₹160 Cr as on March 2024
Sun Pharmaceuticals Industries Ltd(16.71%), Lupin Ltd(6%), Max Healthcare Institute Ltd Ordinary Shares(5.74%), Dr Reddy's Laboratories Ltd(5.38%), Mankind Pharma Ltd(5.15%) as on March 2024
The alpha ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
ITI Pharma and Healthcare Fund Direct Growth | 4.18 | - | - |
As on March 2024
The alpha for ITI Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
ITI Pharma and Healthcare Fund Direct Growth | 0.82 | - | - |
As on March 2024
The Beta for ITI Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
ITI Pharma and Healthcare Fund Direct Growth | 2.99 | - | - |
As on March 2024
The sharpe ratio for ITI Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
ITI Pharma and Healthcare Fund Direct Growth | 12.79 | - | - |
As on March 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
The Exit load of ITI Pharma and Healthcare Fund Direct Growth is 1%